Abbvie Inc. vs Abbott Laboratories
ABBV vs ABT — side-by-side comparison from reported financials. ABBV leads 5, ABT leads 7 of 12 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Abbott Laboratories
ABT · Healthcare
$99.78+1.31%Solid
| Metric | ABBV | ABT |
|---|---|---|
| Price | $276.43 | $99.78 |
| Market cap | $488B | $173B |
| Revenue (TTM) | $64.4B | $46.6B |
| Revenue growth | +1.8% | +0.5% |
| Net margin | 9.8% | 11.6% |
| Free cash flow | $18.2B | $7.82B |
| Net cash (debt) | ($56.2B) | ($957M) |
| 1-year price return | +19.8% | -25.2% |
| P/E | 77.4 | 31.8 |
| P/E vs own history (cheap-side %) | 23% | 44% |
| Dividend yield | 2.45% | 2.47% |
| Return on equity | 96% | 11% |
| Altman Z-score | 2.33 | 2.84 |
| CV checks passed | 9 of 11 | 10 of 11 |
| Employees | 57,000 | 115,000 |
Full résumé-style profiles: ABBV CV · ABT CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.